A new study for newly diagnosed myeloma patients is opening with the goal to inducing deep remissions using a four drug combination as initial treatment. This Phase 2 study will have two arms. Both groups will begin therapy with dexamethasone, lenalidomide (Revlimid), daratumumab (Darzalex), and carfilzomib (Kyprolis). The KRdD combination will be given in four 28-day induction cycles. After completion of this induction therapy, one arm of patients will receive an autologous stem cell transplant, and one arm will not.
If patients still have detectable disease after their transplant, they are able to receive additional therapy with KRdD until they become minimal residual disease (MRD) negative, up to twelve cycles. The non-transplant arm of patients will have the same opportunity to receive additional cycles of KRdD, with their MRD status being checked in between each cycle.
This trial is seeking 82 patients with newly diagnosed, untreated multiple myeloma and adequate renal/hepatic function. Follow the link below for full inclusion/exclusion criteria and to learn more about this study. You can also call SparkCures with any questions at (888) 828-2206.